Copeptin-Troponin Composite Model Calculator
- Copeptin–Troponin Composite Model: Explanation and Clinical Context
The Copeptin–Troponin Composite Model refers to a dual‑biomarker approach combining measurement of copeptin (a stable surrogate marker of arginine‑vasopressin release) and high‑sensitivity cardiac troponin I (hs‑cTnI) on admission in patients with suspected acute cardiac injury or other cardiocirculatory stress. The rationale is that while troponin indicates myocardial injury/necrosis, copeptin reflects neuroendocrine stress and haemodynamic perturbation, thus providing complementary prognostic information. Several studies have shown that elevated admission levels of both copeptin and hs‑cTnI stratify patients into higher risk categories for adverse outcomes (including death, ICU admission or major adverse cardiovascular events) compared to either biomarker alone.
In practical terms, a patient presenting with a copeptin level above the chosen threshold (e.g., > 10 pmol/L) and a hs‑cTnI level above threshold (e.g., > 16.8 ng/L) may be categorised as “High risk” and warrant more intensive monitoring or early intervention, whereas patients below both thresholds may be considered “Low risk”. The “Intermediate risk” group comprises those in whom only one biomarker is elevated or borderline. It is crucial to emphasise that such biomarker‑based models should be used as adjuncts to—not replacements for—clinical assessment, ECG findings, imaging, and other risk stratification tools.
Reference:
Mu D, Cheng X, Qiu L, et al. Copeptin as a Diagnostic and Prognostic Biomarker in Cardiovascular Diseases. Front Cardiovasc Med. 2022;9:901990. doi:10.3389/fcvm.2022.901990.
Ricci F, Di Scala R, Massacesi C, et al. High‑sensitivity troponin I with or without ultra‑sensitive copeptin: comparison of single‑sampling strategies for instant rule‑out of AMI. Front Cardiovasc Med. 2022;9:895421. doi:10.3389/fcvm.2022.895421.
Kaufmann CC, et al. Improvement of outcome prediction of hospitalized patients using admission levels of hs‑cTnI and copeptin. Eur Heart J. 2021;42(Supplement 1):ehab724.3393.
Discussion
No discussions yet. Be the first to comment.
Create Note
Notes are stored privately on your device only. No login required. Nothing is uploaded or shared.